EZH2过表达在MCF-7获得性耐药中的作用

doi:10.11904/j.issn.1002-3070.2016.02.006

实用肿瘤学杂志 ›› 2016, Vol. 30 ›› Issue (2): 123-127.doi: 10.11904/j.issn.1002-3070.2016.02.006

EZH2过表达在MCF-7获得性耐药中的作用

赵玲, 贺金奇, 白淑平, 郭丽, 王晓红

哈尔滨医科大学大附属肿瘤医院肿瘤内科(哈尔滨 150081)

收稿日期:2016-01-25 出版日期:2016-04-28 发布日期:2016-04-28
通讯作者: 王晓红,E-mail:michellestudy@163.com
作者简介:赵玲,女,(1981-),博士,主治医师,从事肿瘤内科学的研究
基金资助:
黑龙江省卫生计生委科研课题(2014-371)

The effect of EZH2 overexpression on acquired drug resistance in MCF-7 cells

ZHAO Ling, HE Jinqi, BAI Shuping, GUO Li, WANG Xiaohong

Department of Medical Oncology,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150040,China

Received:2016-01-25 Online:2016-04-28 Published:2016-04-28

摘要/Abstract

摘要： 目的探讨EZH2过表达在MCF-7/ADR获得性耐药中的作用。方法应用荧光定量PCR技术和Western blot技术分别检测EZH2在MCF-7和MCF-7/ADR中的mRNA和蛋白的相对表达量。将带有报告基因eGFP的EZH2 shRNA、EZH2 shRNA-scramble质粒分别转染MCF-7/ADR细胞后,用G418筛选获得稳转细胞株,应用荧光定量PCR技术验证EZH2 shRNA组EZH2 mRNA表达是否被抑制。采用WST-1方法检测EZH2 shRNA、EZH2 shRNA-scramble和阴性对照组细胞对阿霉素敏感性的变化情况。结果 MCF-7/ADR中EZH2 mRNA相对表达量约为MCF-7的2.52±1.523倍,MCF-7/ADR中EZH2蛋白相对表达量约为MCF-7的1.58±0.58倍,差异均有统计学意义(P＜0.05)。EZH2 shRNA组稳转的细胞株EZH2 mRNA的抑制率约为84%(P＜0.05),加入阿霉素后细胞增殖能力约下降25%(P＜0.05),而EZH2 shRNA-scramble组和阴性对照组加入阿霉素后细胞增殖能力无明显变化。结论在MCF-7/ADR细胞中EZH2 mRNA和蛋白的相对表达量较MCF-7细胞高。沉默EZH2的表达有可能逆转MCF-7/ADR细胞对阿霉素的耐药性。

关键词: EZH2, MCF-7/ADR, 阿霉素耐药

Abstract: Objective To explore the effect of EZH2 overexpression on acquired drug resistance in MCF-7 cells.Methods The relative expressions of EZH2 mRNA and protein of MCF-7 and MCF-7/ADR were detected respectively by real time fluorescence quantitative PCR(RTFQPCR)and Western-blot.After EZH2 shRNA and EZH2 shRNA-scramble plasmid vectors with reporter gene EGFP were transfected into MCF-7/ADR cells,the stable cell line was screened by G4l8.RTFQPCR was used to validate whether the EZH2 mRNA in EZH2 shRNA group was supressed.The differences of the effect of adriamycin on cell proliferation were evaluated among EZH2 shRNA goup,EZH2 shRNA-scramble group and negative control groups using WST-1 assays.Results The EZH2 mRNA and protein expression levels in MCF-7/ADR cells were 2.52±1.523 and 1.58±0.58 folds of those in MCF-7cells.The differences were significant(P＜0.05).After the EZH2 shRNA plasmid was stably expressed in MCF-7/ADR cells,the expressions of EZH2 mRNA were decreased by 84%(P＜0.05)and the cell proliferation was decreased by 25% after adriamycin(P＜0.05),However there were no significant changes of cell proliferation in EZH2 shRNA-scramble group and negative control groups after adriamycin.Conclusion EZH2 was overexpressed in MCF-7/ADR cells compared with MCF-7 cells.Silencing EZH2 may effectively reverse the resistance of MCF-7/ADR cells to adriamycin.

Key words: EZH2, MCF-7/ADR, Adriamycin resistance

中图分类号:

R737.9

赵玲, 贺金奇, 白淑平, 郭丽, 王晓红. EZH2过表达在MCF-7获得性耐药中的作用[J]. 实用肿瘤学杂志, 2016, 30(2): 123-127.

ZHAO Ling, HE Jinqi, BAI Shuping, GUO Li, WANG Xiaohong. The effect of EZH2 overexpression on acquired drug resistance in MCF-7 cells[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 123-127.

参考文献

1 Ding X,Wang X,Sontag S,et al.The polycomb protein Ezh2 impacts on induced pluripotent stem cell generation[J].Stem Cells Dev,2014,23(9):931-940.
2 Pang J,Toy KA,Griffith KA,et al.Invasive breast carcinomas in Ghana:high frequency of high grade,basal-like histology and high EZH2 expression[J].Breast Cancer Res Treat,2012,135(1):59-66.
3 Panousis D,Patsouris E,Lagoudianakis E,et al.The value of TOP2A,EZH2 and paxillin expression as markers of aggressive breast cancer:relationship with other prognostic factors[J].Eur J Gynaecol Oncol,2011,32(2):156-159.
4 Sellers WR,Loda M.The EZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer[J].Cancer Cell,2002,2(5):349-350.
5 van Kemenade FJ,Raaphorst FM,Blokzijl T,et al.Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma[J].Blood,2001,97(12):3896-3901.
6 Liudmila LK,Rutger JJ,Jarom H,et al.The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer[J].Carcinogenesis,2010,9(32):1567-1575.
7 Liu L,Xu Z,Zhong L,et al.Enhancer of zeste homolog 2(EZH2)promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma[J].BJU Int,2016,117(2):351-362.
8 胡沙,王静,李智敏,等.EZH2基因在人卵巢癌顺铂耐药株中的表达及其对细胞耐药性的影响[J].肿瘤,2010,9(30):748-751.
9 田金华,王晶,宋成文,等.EZH2与人卵巢上皮性癌细胞顺铂耐药性的相关性[J].华南国防医学杂志,2011,25(3):193-195.
10 Cai L,Wang Z,Liu D.Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression[J].Tumour Biol,2015,2[Epub ahead of print].
11 Ginsburg OM,Love RR.Breast cancer:a neglected disease for the majority of affected women worldwide[J].Breast J,2011,17(3):289-295.
12 Lund K,Adams PD,Copland M.EZH2 in normal and malignant hematopoiesis[J].Leukemia,2014,28(1):44-49.
13 Tan JZ,Yan Y,Wang XX,et al.EZH2:biology,disease,and structure-based drug discovery[J].Acta Pharmacol Sin,2014,35(2):161-174.
14 Margueron R,Reinberg D.The Polycomb complex PRC2 and its mark in life[J].Nature,2011,469(7330):343-349.
15 Fu YB,Chen J,Pang B,et al.EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer[J].Cell Biochemistry and Biophysics,2015,71(1):105-112.
16 Gonzalez ME,Duprie ML,Krueger H,et al.Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer[J].Cancer Res,2011,71(6):2360-2370.
17 Raaphorst FM,Meijer CJ,Fieret E,et al.Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene[J].Neoplasia,2003,5(6):481-488.
18 Yaser RH,Anil KS,Sudeshna B,et al.Clinical and biological relevance of EZH2 in triple negative breast cancer[J].Hum Pathol,2012,43(10):1638-1644.
19 Zhou W,Wang J,Man WY,et al.SiRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells[J].Asian Pac J Cancer Prev,2015,16(6):2425-2430.
20 Wang HL,Yu YH,Chen C,et al.Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes[J].Mol Med Rep,2015,12(2):2503-2510.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[3]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[4]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[5]	白玉贤, 马仲娟, 苏颖玲, 慕安国, 谢蕊. 胃癌患者FHIT、hMLH1、p16、RAR-beta、Reprimo和TIMP3基因的甲基化研究[J]. 实用肿瘤学杂志, 2019, 33(1): 8-13.
[6]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[7]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[8]	王志, 刘忠卫, 曾雪芸, 隋明洁, 廖静怡, 李月欢, 黄卫东, 刘国祥. 基于EQ-5D-5L的结直肠癌癌前病变患者健康相关生命质量研究[J]. 实用肿瘤学杂志, 2018, 32(4): 320-326.
[9]	范宁宁, 耿敬姝. 长链非编码RNA MEG3在人胶质瘤细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(3): 219-223.
[10]	闫石, 霍明鸣, 庞慧, 李焱, 蔡莉. p53对绝经后HR阳性、HER-2阳性术后乳腺癌患者内分泌药物疗效的预测价值[J]. 实用肿瘤学杂志, 2018, 32(3): 234-213.
[11]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[12]	靳俊杰, 安静, 曹涤非, 宋爱利, 赵丽丽, 刘兆良. 组蛋白赖氨酸转移酶KAT6B基因shRNA慢病毒载体的构建与鉴定[J]. 实用肿瘤学杂志, 2018, 32(1): 1-6.
[13]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[14]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[15]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.

EZH2过表达在MCF-7获得性耐药中的作用

The effect of EZH2 overexpression on acquired drug resistance in MCF-7 cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价